

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/435	A1	(11) International Publication Number: WO 99/42104 (43) International Publication Date: 26 August 1999 (26.08.99)
(21) International Application Number: PCT/JP99/00681 (22) International Filing Date: 17 February 1999 (17.02.99) (30) Priority Data: PP 1955 23 February 1998 (23.02.98) AU PP 2992 16 April 1998 (16.04.98) AU (71) Applicant (for all designated States except US): FUJISAWA PHARMACEUTICAL CO., LTD. [JP/JP]; 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP). (72) Inventor; and (75) Inventor/Applicant (for US only): SAKUMA, Shozo [JP/JP]; 12-13, Nakaya-cho, Nishinomiya-shi, Hyogo 662-0868 (JP). (74) Agent: SEKI, Hideo; Fujisawa Pharmaceutical Co., Ltd., Osaka Factory, 1-6, Kashima 2-chome, Yodogawa-ku, Osaka-shi, Osaka 532-8514 (JP).		(81) Designated States: JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: USE OF MACROLIDE COMPOUNDS FOR TREATING GLAUCOMA (57) Abstract Macrolide compounds, such as the FK506 Substance and its related compounds, are provided for the prevention or treatment of eye diseases, particularly glaucoma. Composition containing such compounds is also disclosed.		

THIS PAGE BLANK (USPTO)

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

THIS PAGE BLANK (USPTO)

DESCRIPTION

USE OF MACROLIDE COMPOUNDS FOR TREATING GLAUCOMA

TECHNICAL FIELD

This invention relates to a new use of macrolide compounds for eye diseases. More specifically, this invention relates to a new use of macrolide compounds for preventing or treating glaucoma.

BACKGROUND ART

Glaucoma is a group of eye diseases characterized by an increase in intraocular pressure that causes pathological changes in the optic disk and typical defects in the field of vision. Normally, primary glaucoma (e.g., primary angle-closure glaucoma, primary open-angle glaucoma, etc.), secondary glaucoma (e.g., secondary angle-closure glaucoma, secondary open-angle glaucoma, etc.) and congenital glaucoma are exemplified as the particular ones thereof.

The progressive optic neuropathy that is accompanied by normal intraocular pressure, open iridocorneal angles and no evidence of other systemic disease is commonly termed normal-pressure glaucoma. 25% of patients suffering from glaucoma are regarded as the ones suffering normal-pressure glaucoma. Patients suffering from normal-pressure glaucoma also have neuronal damage, which results in loss of vision. However, the mechanism by which the damage occurs is not clearly understood.

Many macrolide compounds having immunosuppressive

THIS PAGE BLANK (USPTO)

activity are already known. For example, the tricyclic macrolide compound and its pharmaceutically acceptable salt for use in accordance with this invention is known to have excellent immunosuppressive activity, antimicrobial activity and other pharmacological activities and, as such, be of value for the treatment or prevention of rejection reactions by transplantation of organs or tissues, graft-vs.-host diseases, autoimmune diseases, and infectious diseases [EP-A-0184162, EP-A-0323042, etc.].

DISCLOSURE OF INVENTION

The inventors of this invention have surprisingly found that the macrolide compounds mentioned here-in-below are useful for preventing or treating eye diseases, such as, glaucoma, more particularly, normal-pressure glaucoma.


Accordingly, this invention provides a new use of the macrolide compounds for preventing or treating glaucoma.

Further, this invention provides a prophylactic or therapeutic agent for glaucoma, which comprises the macrolide compounds.

Still further, this invention provides a method for preventing or treating glaucoma, which comprises administering said macrolide compounds to mammals.

As a particular example of the macrolide compounds, the tricyclic compound of the following formula (I) can be exemplified.

THIS PAGE BLANK (USPTO)



(wherein each of adjacent pairs of R^1 and R^2 , R^3 and R^4 , and R^5 and R^6 independently

(a) is two adjacent hydrogen atoms, but R^2 may also be an alkyl group or

(b) may form another bond formed between the carbon atoms to which they are attached;

R^7 is a hydrogen atom, a hydroxy group, a protected hydroxy group, or an alkoxy group, or an oxo group together with R^1 ;

R^8 and R^9 are independently a hydrogen atom or a hydroxy group;

R^{10} is a hydrogen atom, an alkyl group, an alkyl group substituted by one or more hydroxy groups, an alkenyl group, an alkenyl group substituted by one or more hydroxy groups, or an alkyl group substituted by an oxo group;

X is an oxo group, (a hydrogen atom and a hydroxy group), (a hydrogen atom and a hydrogen atom), or a group represented by the formula $-\text{CH}_2\text{O}-$;

THIS PAGE BLANK (USPTO)

Y is an oxo group, (a hydrogen atom and a hydroxy group),
(a hydrogen atom and a hydrogen atom), or a group
represented by the formula $N-NR^{11}R^{12}$ or $N-OR^{13}$;
 R^{11} and R^{12} are independently a hydrogen atom, an alkyl group,
an aryl group or a tosyl group;
 R^{13} , R^{14} , R^{15} , R^{16} , R^{17} , R^{18} , R^{19} , R^{22} and R^{23} are independently a hydrogen
atom or an alkyl group;
 R^{24} is an optionally substituted ring system which may contain
one or more heteroatoms;
n is an integer of 1 or 2; and
in addition to the above definitions, Y, R^{10} and R^{23} , together
with the carbon atoms to which they are attached, may represent
a saturated or unsaturated 5- or 6-membered nitrogen, sulfur
and/or oxygen containing heterocyclic ring optionally
substituted by one or more groups selected from the group
consisting of an alkyl, a hydroxy, an alkoxy, a benzyl, a group
of the formula $-CH_2Se(C_6H_5)$, and an alkyl substituted by one or
more hydroxy groups.

Preferable R^{24} may be cyclo(C_{5-7})alkyl group, and the
following ones can be exemplified.

- (a) a 3,4-di-oxo-cyclohexyl group;
- (b) a 3- R^{20} -4- R^{21} -cyclohexyl group,

in which R^{20} is hydroxy, an alkoxy group, or a

$-OCH_2OCH_2CH_2OCH_3$ group, and

R^{21} is hydroxy, $-OCN$, an alkoxy group, a

THIS PAGE BLANK (USPTO)

heteroaryloxy which may be substituted by suitable substituents, a $-OCH_2OCH_2CH_2OCH_3$ group, a protected hydroxy group, chloro, bromo, iodo, aminooxalyloxy, an azido group, p-tolyloxythiocarbonyloxy, or $R^{25}R^{26}CHCOO-$,

in which R^{25} is optionally protected hydroxy or protected amino, and

R^{26} is hydrogen or methyl, or

R^{20} and R^{21} together form an oxygen atom in an epoxide ring; or

(c) cyclopentyl group substituted by methoxymethyl, optionally protected hydroxymethyl, acyloxymethyl

(in which the acyl moiety optionally contains either a dimethylamino group which may be quaternized, or a carboxy group which may be esterified), one or more amino and/or hydroxy groups which may be protected, or aminooxalyloxymethyl. A preferred example is a 2-formyl-cyclopentyl group.

The definitions used in the above general formula (I) and the specific and preferred examples thereof are now explained and set forth in detail.

The term "lower" means, unless otherwise indicated, a group having 1 to 6 carbon atoms.

Preferable examples of the "alkyl groups" and an alkyl

THIS PAGE BLANK (USPTO)

moiety of the "alkoxy group" include a straight or branched chain aliphatic hydrocarbon residue, for example, a lower alkyl group such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, neopentyl and hexyl.

Preferable examples of the "alkenyl groups" include a straight or branched chain aliphatic hydrocarbon residue having one double-bond, for example, a lower alkenyl group such as vinyl, propenyl (e.g., allyl group), butenyl, methylpropenyl, pentenyl and hexenyl.

Preferable examples of the "aryl groups" include phenyl, tolyl, xylyl, cumenyl, mesityl and naphthyl.

Preferable protective groups in the "protected hydroxy groups" and the "protected amino" are 1-(lower alkylthio)-(lower)alkyl group such as a lower alkylthiomethyl group (e.g., methylthiomethyl, ethylthiomethyl, propylthiomethyl, isopropylthiomethyl, butylthiomethyl, isobutylthiomethyl, hexylthiomethyl, etc.), more preferably C_1 - C_4 alkylthiomethyl group, most preferably methylthiomethyl group;

trisubstituted silyl group such as a tri(lower)alkylsilyl (e.g., trimethylsilyl, triethylsilyl, tributylsilyl, tert-butyl dimethylsilyl, tri-tert-butylsilyl, etc.) or lower alkyl-diarylsilyl (e.g., methyldiphenylsilyl, ethyldiphenylsilyl, propyldiphenylsilyl, tert-butyl diphenylsilyl, etc.), more preferably tri(C_1 - C_4)alkylsilyl group and C_1 - C_4 alkyl diphenylsilyl group, most preferably tert-butyl dimethylsilyl group and tert-butyl diphenylsilyl group;

THIS PAGE BLANK (USPTO)

and an acyl group such as an aliphatic, aromatic acyl group or an aliphatic acyl group substituted by an aromatic group, which are derived from a carboxylic acid, sulfonic acid or carbamic acid.

Examples of the aliphatic acyl groups include a lower alkanoyl group optionally having one or more suitable substituents such as carboxy, e.g., formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, carboxyacetyl, carboxypropionyl, carboxybutyryl, carboxyhexanoyl, etc.;

a cyclo(lower)alkoxy(lower)alkanoyl group optionally having one or more suitable substituents such as lower alkyl, e.g., cyclopropyloxyacetyl, cyclobutyloxypropionyl, cycloheptyloxybutyryl, menthyloxyacetyl, menthyloxypropionyl, menthyloxybutyryl, menthyloxypentanoyl, menthyloxyhexanoyl, etc.; a camphorsulfonyl group; or a lower alkylcarbamoyl group having one or more suitable substituents such as carboxy or protected carboxy, for example, carboxy(lower)alkylcarbamoyl group (e.g., carboxymethylcarbamoyl, carboxyethylcarbamoyl, carboxypropylcarbamoyl, carboxybutylcarbamoyl, carboxypentylcarbamoyl, carboxyhexylcarbamoyl, etc.), tri-(lower)alkylsilyl(lower)alkoxycarbonyl(lower)alkylcarbamoyl group (e.g., trimethylsilylmethoxycarbonylethylcarbamoyl, trimethylsilylethoxycarbonylpropylcarbamoyl, triethylsilylethoxycarbonylpropylcarbamoyl, tert-butyl dimethylsilylethoxycarbonylpropylcarbamoyl, tri-

THIS PAGE BLANK (USPTO)

methylsilylpropoxycarbonylbutylcarbamoyl, etc.) and so on.

Examples of the aromatic acyl groups include an aroyl group optionally having one or more suitable substituents such as nitro, e.g., benzoyl, toluoyl, xyloyl, naphthoyl, nitrobenzoyl, dinitrobenzoyl, nitronaphthoyl, etc.; and an arenesulfonyl group optionally having one or more suitable substituents such as halogen, e.g., benzenesulfonyl, toluenesulfonyl, xylenesulfonyl, naphthalenesulfonyl, fluorobenzenesulfonyl, chlorobenzenesulfonyl, bromobenzenesulfonyl, iodobenzenesulfonyl, etc.

Examples of the aliphatic acyl groups substituted by an aromatic group include ar(lower)alkanoyl group optionally having one or more suitable substituents such as lower alkoxy or trihalo(lower)alkyl, e.g., phenylacetyl, phenylpropionyl, phenylbutyryl, 2-trifluoromethyl-2-methoxy-2-phenylacetyl, 2-ethyl-2-trifluoromethyl-2-phenylacetyl, 2-trifluoromethyl-2-propoxy-2-phenylacetyl, etc.

More preferable acyl groups among the aforesaid acyl groups are C₁-C₄ alkanoyl group optionally having carboxy, cyclo(C₅-C₆) alkoxy(C₁-C₄) alkanoyl group having two (C₁-C₄) alkyls at the cycloalkyl moiety, camphorsulfonyl group, carboxy-(C₁-C₄) alkylcarbamoyl group, tri(C₁-C₄) alkylsilyl(C₁-C₄)-alkoxycarbonyl(C₁-C₄) alkylcarbamoyl group, benzoyl group optionally having one or two nitro groups, benzenesulfonyl group having halogen, or phenyl(C₁-C₄) alkanoyl group having C₁-C₄ alkoxy and trihalo(C₁-C₄) alkyl group. Among these, the most

THIS PAGE BLANK (USPTO)

preferable ones are acetyl, carboxypropionyl, menthyloxyacetyl, camphorsulfonyl, benzoyl, nitrobenzoyl, dinitrobenzoyl, iodobenzenesulfonyl and 2-trifluoromethyl-2-methoxy-2-phenylacetyl.


Preferable examples of the "5- or 6-membered nitrogen, sulfur and/or oxygen containing heterocyclic ring" include a pyrrolyl group and a tetrahydrofuryl group.

The ticyclic compounds (I) and its pharmaceutically acceptable salt for use in accordance with this invention are well known to have excellent immunosuppressive activity, antimicrobial activity and other pharmacological activities and, as such, be of value for the treatment or prevention of rejection reactions by transplantation of organs or tissues, graft-vs-host diseases, autoimmune diseases, and infectious diseases [EP-A-0184162, EP-A-0323042, EP-A-423714, EP-A-427680, EP-A-465426, EP-A-480623, EP-A-532088, EP-A-532089, EP-A-569337, EP-A-626385, WO89/05303, WO93/05058, WO96/31514, WO91/13889, WO91/19495, WO93/5059, etc.] , the disclosures of which are incorporated herein by reference.

Particularly, the compounds which are designated as FR900506 (=FK506), FR900520 (ascomycin), FR900523, and FR900525 are products produced by microorganisms of the genus Streptomyces, such as Streptomyces tsukubaensis No. 9993 [deposited with National Institute of Bioscience and Human Technology Agency of Industrial Science and Technology (formerly

THIS PAGE BLANK (USPTO)

Fermentation Research Institute Agency of Industrial Science and Technology), at 1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki, Japan, date of deposit October 5, 1984, accession number FERM BP-927] or Streptomyces hygrosopicus subsp. yakushimaensis No. 7238 [deposited with National Institute of Bioscience and Human Technology Agency of Industrial Science and Technology (formerly Fermentation Research Institute Agency of Industrial Science and Technology), at 1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki, Japan, date of deposit January 12, 1985, accession number FERM BP-928][EP-A-0184162]. The FK506 Substance (general name: tacrolimus) of the following chemical formula, in particular, is a representative compound.



Chemical name: 17-allyl-1,14-dihydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

THIS PAGE BLANK (USFIC)

The preferred examples of the tricyclic compounds (I) are the ones, wherein each of adjacent pairs of R^3 and R^4 or R^5 and R^6 independently form another bond formed between the carbon atoms to which they are attached;

each of R^8 and R^{23} is independently a hydrogen atom;

R^9 is a hydroxy group;

R^{10} is a methyl group, an ethyl group, a propyl group or an allyl group;

X is (a hydrogen atom and a hydrogen atom) or an oxo group;

Y is an oxo group;

each of R^{14} , R^{15} , R^{16} , R^{17} , R^{18} , R^{19} , and R^{22} is a methyl group;

R^{24} is a 3- R^{20} -4- R^{21} -cyclohexyl group,

in which R^{20} is hydroxy, an alkoxy group, or a

-OCH₂OCH₂CH₂OCH₃ group, and

R^{21} is hydroxy, -OCN, an alkoxy group, a

heteroaryloxy which may be substituted by

suitable substituents, a -OCH₂OCH₂CH₂OCH₃ group,

a protected hydroxy group, chloro, bromo, iodo,

aminooxalyloxy, an azido group, p-

tolyloxythiocarbonyloxy, or $R^{25}R^{26}CHCOO-$,

in which R^{25} is optionally protected hydroxy

or protected amino, and

R^{26} is hydrogen or methyl, or

R^{20} and R^{21} together form an oxygen atom in an epoxide ring; and

THIS PAGE BLANK (USPTO)

n is an integer of 1 or 2.

The most preferable tricyclic compounds (I) is, in addition to FK506, ascomycin derivatives such as halogenated-ascomycin (e.g., 33-epi-chloro-33-desoxyascomycin), which is disclosed in EP 427,680, example 66a.

As the other preferable example of the macrolide as immunosuppressants, rapamycin [THE MERCK INDEX (12th edition), No. 8288] and its derivatives can be exemplified. Preferred example of the derivatives is an O-substituted derivative in which the hydroxy in position 40 of formula A illustrated at page 1 of WO 95/16691, incorporated herein by reference, is replaced by $-OR_1$ in which R_1 is hydroxyalkyl, hydroalkoxyalkyl, acylaminoalkyl and aminoalkyl; for example 40-O-(2-hydroxy)ethyl-rapamycin, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin and 40-O-(2-acetaminoethyl)-rapamycin. These O-substituted derivatives may be produced by reacting rapamycin (or dihydro or deoxo-rapamycin) with an organic radical attached to a leaving group (for example RX where R is the organic radical which is desired as the O-substituent, such as an alkyl, allyl, or benzyl moiety, and X is a leaving group such as $CCl_3C(NH)O$ or CF_3SO_3) under suitable reaction conditions. The conditions may be acidic or neutral conditions, for example in the presence of an acid like trifluoromethanesulfonic acid, camphorsulfonic acid, p-

THIS PAGE BLANK (USPTO)

toluenesulfonic acid or their respective pyridinium or substituted pyridinium salts when X is $\text{CCl}_3\text{C}(\text{NH})\text{O}$ or in the presence of a base like pyridine, a substituted pyridine, diisopropylethylamine or pentamethylpiperidine when X is CF_3SO_3 . The most preferable one is 40-O-(2-hydroxy)ethyl rapamycin, which is disclosed in W094/09010, the disclosure of which is incorporated herein by reference.

The tricyclic compounds(I), and rapamycin and its derivatives, have a similar basic structure, i.e., tricyclic macrolide structure, and at least one of the similar biological properties (for example, immunosuppressive activity).

The tricyclic compounds(I), and rapamycin and its derivatives, may be in a form of its salt, which includes conventional non-toxic and pharmaceutically acceptable salt such as the salt with inorganic or organic bases, specifically, an alkali metal salt such as sodium salt and potassium salt, an alkali earth metal salt such as calcium salt and magnesium salt, an ammonium salt and an amine salt such as triethylamine salt and N-benzyl-N-methylamine salt.

With respect to the macrolide compounds usable in the present invention, it is to be understood that there may be conformers and one or more stereoisomers such as optical and geometrical isomers due to asymmetric carbon atom(s) or double

THIS PAGE BLANK (USPTO)

bond(s), and such conformers and isomers are also included within the scope of the present invention. And further, the macrolide compounds can be in the form of a solvate, which is included within the scope of the present invention. The solvate preferably include a hydrate and an ethanolate.

The macrolide compounds usable in the present invention may be administered as pure compounds or mixtures of compounds or preferably, in a pharmaceutical vehicle or carrier.

The pharmaceutical compositions of this invention can be used in the form of a pharmaceutical preparation, for example, in solid, semisolid or liquid form, which contains the macrolide compounds of the present invention, as an active ingredient, in admixture with an organic or inorganic carrier or excipient suitable for external(topical), enteral, intravenous, intramuscular, or parenteral applications. The active ingredient may be compounded, for example, with the usual non-toxic, pharmaceutically acceptable, carriers for tablets, pellets, capsules, eye drops, suppositories, solutions (saline, for example), emulsion, suspensions (olive oil, for example), ointment and any other form suitable for use. The carriers which can be used are water, glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, colloidal silica, potato starch, urea and other carriers suitable for use in manufacturing preparations, in solid, semisolid, or liquid form, and in addition auxiliary,

THIS PAGE BLANK (USPTO)

stabilizing, thickening and coloring agents and perfumes may be used. The active object compound is included in the pharmaceutical composition in an effective amount sufficient to produce the desired effect upon the process or condition of the disease.

Mammals which may be treated using the method of the present invention include livestock mammals such as cows, horses, etc., domestic animals such as dogs, cats, rats, etc. and humans.

For applying this composition to a human, it is preferable to apply it by external (topical) administration, particularly in the form of eye drops.

While the dosage of therapeutically effective amount of the macrolide compounds varies from and also depends upon the age and condition of each individual patient to be treated, a daily dose of about 0.0001-1000 mg, preferably 0.001-500 mg and more preferably 0.01-100 mg. of the active ingredient is generally given for treating diseases, and an average single dose of about 0.001-0.01mg, 0.2-0.5 mg, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg, 250 mg and 500 mg is generally administered. Daily doses for chronic administration in humans will be in the range of about 0.1-0.3 mg/kg/day.

The most suitable disease among glaucoma is normal-pressure glaucoma. Normal-pressure glaucoma patients have been found to have increased serum immunoreactivity to human Heat Shock Proteins (Hsp), particularly Hsp60. Therefore, Glaucomatous optic neuropathy in a cohort of patients with

THIS PAGE BLANK (USPTO)

normal-pressure glaucoma deems to involve aberrant autoimmunity (Am. J. Ophthalmol, 1998; 125 145-157), the disclosure of which is incorporated herein by reference.

The effectiveness of the macrolide compounds on normal-pressure glaucoma can be confirmed by evaluating the inhibiting activity on such aberrant autoimmunity, as well as the direct treatment of patients suffering from normal-pressure glaucoma. Particularly, the eye drop prepared in the below mentioned Example 2, which contains FK506 Substance, can inhibit the aberrant autoimmunity and is quite effective for treating glaucoma, particularly normal-pressure glaucoma.

The following examples are given for the purpose of illustrating the present invention.

Example 1

FK 506 Substance	1 g
Hydroxypropyl methylcellulose 2910 (TC-5R)	1 g
Lactose	2 g
Croscarmellose sodium (Ac-Di-Sol)	1 g

The FK 506 Substance (1 g) was dissolved in ethanol (10 ml), and thereto was added hydroxypropyl methylcellulose 2910 (TC-5R) (1 g) to prepare a suspension. To this suspension was added dichloromethane (5 ml) to prepare a homogeneous solution. Lactose (2 g) and croscarmellose sodium (Trade Mark: Ac-Di-

THIS PAGE BLANK (USPTO)

Sol, maker: Asahi Chemical Industry) were homogeneously suspended to this solution, and then the organic solvent was removed by evaporation. The residual product was dried under reduced pressure for 10 hours by vacuum dryer, milled for 2 minutes by coffee mill and then passed through a sieve (32 mesh) to give the solid dispersion composition of FK 506 Substance (5 g). This composition was capsulated by a conventional manner to provide capsules containing 1 mg or 5 mg of FK 506 Substance per each capsule.

Example 2


FK 506 Substance (fine powder)	1 mg
Polysorbate 80	0.5mg
Polyvinyl alcohol	2.8mg
Benzalkonium chloride	0.1mg
Sodium chloride	8.6mg
pH5.25 Phosphate buffer	to 1 ml

An aqueous suspending eye drop containing the above-mentioned ingredients is prepared according to a conventional manner shown in EP-A-0406791, the disclosure of which is incorporated herein by reference.

THIS PAGE BLANK (USPTO)

CLAIMS

1. A use of macrolide compounds for manufacturing a medicament for preventing or treating glaucoma.
2. The use of Claim 1, in which the macrolide compounds is the tricyclic compounds of the following formula (I) :



(wherein each of adjacent pairs of R^1 and R^2 , R^3 and R^4 , and R^5 and R^6 independently

(a) is two adjacent hydrogen atoms, but R^2 may also be an alkyl group or

(b) may form another bond formed between the carbon atoms to which they are attached;

R^7 is a hydrogen atom, a hydroxy group, a protected hydroxy group, or an alkoxy group, or an oxo group together with R^1 ;

R^8 and R^9 are independently a hydrogen atom or a hydroxy group;

R^{10} is a hydrogen atom, an alkyl group, an alkyl group substituted by one or more hydroxy groups, an alkenyl group, an alkenyl

THIS PAGE BLANK (USPTO)

group substituted by one or more hydroxy groups, or an alkyl group substituted by an oxo group;

X is an oxo group, (a hydrogen atom and a hydroxy group), (a hydrogen atom and a hydrogen atom), or a group represented by the formula $-\text{CH}_2\text{O}-$;

Y is an oxo group, (a hydrogen atom and a hydroxy group), (a hydrogen atom and a hydrogen atom), or a group represented by the formula $\text{N}-\text{NR}^{11}\text{R}^{12}$ or $\text{N}-\text{OR}^{13}$;

R^{11} and R^{12} are independently a hydrogen atom, an alkyl group, an aryl group or a tosyl group;

R^{13} , R^{14} , R^{15} , R^{16} , R^{17} , R^{18} , R^{19} , R^{22} and R^{23} are independently a hydrogen atom or an alkyl group;

R^{24} is an optionally substituted ring system which may contain one or more heteroatoms;

n is an integer of 1 or 2; and

in addition to the above definitions, Y, R^{10} and R^{23} , together with the carbon atoms to which they are attached, may represent a saturated or unsaturated 5- or 6-membered nitrogen, sulfur and/or oxygen containing heterocyclic ring optionally substituted by one or more groups selected from the group consisting of an alkyl, a hydroxy, an alkoxy, a benzyl, a group of the formula $-\text{CH}_2\text{Se}(\text{C}_6\text{H}_5)$, and an alkyl substituted by one or more hydroxy groups.

3. A method for preventing or treating glaucoma, which comprises administering macrolide compounds to mammals.

THIS PAGE BLANK (USPTO)

4. A pharmaceutical composition for treating or preventing glaucoma, which comprises macrolide compounds in admixture with a carrier or excipient.
5. A process for preparing the pharmaceutical composition of Claim 4, which is characterized by admixing the macrolide compounds with a carrier or excipient.
6. The macrolide compound used in Claims 1 to 5 is FK 506 Substance.
7. The glaucoma in Claims 1 is normal-pressure glaucoma.

THIS PAGE BLANK (USPTO)

INTERNATIONAL SEARCH REPORT

International Application No
PCT/JP 99/00681

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K31/435

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 98 41205 A (CHILDRENS MEDICAL CENTER) 24 September 1998 see abstract see page 18 - page 24 see page 17, line 7 - line 14 see page 31, line 17 - line 20; claims 1-8 ---	1,3-5
X	WO 94 13275 A (MASSACHUSETTS EYE AND EAR INFI ;CHILDRENS MEDICAL CENTER (US)) 23 June 1994 see the whole document, in particular page 13, last compound mentioned ---	1-7
X	EP 0 532 862 A (UNIV LOUISVILLE RES FOUND) 24 March 1993 see abstract see page 2, column 1, line 45 - line 51; claims --- -/--	1,3-5,7

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

29 June 1999

Date of mailing of the international search report

12/07/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Hoff, P

THIS PAGE BLANK (USPTO)

INTERNATIONAL SEARCH REPORT

Internatic Application No
PCT/JP 99/00681

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	G.C.Y. CHIOU: "Recent advances in antiglaucoma drugs" BIOCHEMICAL PHARMACOLOGY, vol. 30, 1981, pages 103-106, XP002107525 see page 105, left-hand column, paragraph 2 - right-hand column, paragraph 1 ---	1,3-5,7
X	WO 97 31020 A (GEN HOSPITAL CORP) 28 August 1997 see abstract see page 17, line 24 - page 19, line 11 A see page 28, line 14 - line 25; claims ---	4-6 1-3,7
X	WO 92 19278 A (KURUME UNIVERSITY) 12 November 1992 see the whole document ---	4-6
X	EP 0 484 936 A (FUJISAWA PHARMACEUTICAL CO) 13 May 1992- see the whole document ---	4-6
X	EP 0 184 162 A (FUJISAWA PHARMACEUTICAL CO) 11 June 1986 cited in the application see abstract see page 66, line 33 - page 67, line 6; claims 1,15-18; examples ---	4-6
X	PLEYER U ET AL: "Ocular absorption of topically applied FK506 from liposomal and oil formulations in the rabbit eye 'published erratum appears in Invest Ophthalmol Vis Sci 1993 Nov;34(12):3481!." INVESTIGATIVE OPHTHALMOLOGY AND VISUAL SCIENCE, (1993 AUG) 34 (9) 2737-42. JOURNAL CODE: GWI. ISSN: 0146-0404., XP002107526 United States A see the whole document ---	4-6 1-3,7
A	SALAS-PRATO M ET AL: "Inhibition by rapamycin of PDGF- and bFGF-induced human tenon fibroblast proliferation in vitro." JOURNAL OF GLAUCOMA, (1996 FEB) 5 (1) 54-9. JOURNAL CODE: CMA. ISSN: 1057-0829., XP002107527 United States see the whole document -----	1,3-5,7

THIS PAGE BLANK (USPTO)

INTERNATIONAL SEARCH REPORT

Intern. application No.

PCT/JP 99/00681

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim 3
is directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
See FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

THIS PAGE BLANK (USPTO)

FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

In view of the large number of compounds which are theoretically contained within the definition "macrolide" of claim 1 the search had to be restricted on economic grounds. The search was limited to the general idea of the invention and to the compounds mentioned in claim 2 (Art. 6 PCT, Guidelines Chapt.II.7, last sentence and Chapt.III,3.7).

Claims searched completely:

2,6

Claims searched incompletely: 1,3,4,5,7

THIS PAGE BLANK (Usp 10)

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/JP 99/00681

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9841205 A	24-09-1998	AU 6566098 A	12-10-1998
WO 9413275 A	23-06-1994	AU 683634 B AU 5741494 A CA 2150933 A EP 0671910 A JP 8506807 T	20-11-1997 04-07-1994 23-06-1994 20-09-1995 23-07-1996
EP 0532862 A	24-03-1993	AT 133336 T AU 653415 B AU 2035092 A CA 2074641 A DE 69207847 D DE 69207847 T DK 532862 T ES 2083030 T HK 1005705 A HU 211218 B IL 102414 A JP 2568962 B JP 5194212 A MX 9204381 A NZ 243679 A SK 230792 A RU 2048812 C US 5387589 A	15-02-1996 29-09-1994 28-01-1993 26-01-1993 07-03-1996 30-05-1996 19-02-1996 01-04-1996 22-01-1999 28-11-1995 04-08-1996 08-01-1997 03-08-1993 01-02-1993 24-06-1997 08-05-1996 27-11-1995 07-02-1995
WO 9731020 A	28-08-1997	NONE	
WO 9219278 A	12-11-1992	CA 2102241 A EP 0581959 A JP 7500570 T US 5514686 A	27-10-1992 09-02-1994 19-01-1995 07-05-1996
EP 0484936 A	13-05-1992	AT 112486 T AU 653556 B AU 8709991 A CA 2054983 A CN 1061907 A DE 69104460 D DE 69104460 T DK 484936 T ES 2061149 T IE 65341 B IL 100011 A JP 2581359 B JP 5155770 A PT 99461 A,B US 5368865 A US 5496564 A HU 210760 B RU 2079304 C	15-10-1994 06-10-1994 14-05-1992 09-05-1992 17-06-1992 10-11-1994 09-02-1995 27-03-1995 01-12-1994 18-10-1995 08-12-1995 12-02-1997 22-06-1993 30-10-1992 29-11-1994 05-03-1996 28-07-1995 20-05-1997
EP 0184162 A	11-06-1986	AT 104984 T AU 592067 B AU 5059685 A CA 1338491 A CN 85109492 A,B	15-05-1994 04-01-1990 12-06-1986 30-07-1996 10-06-1986

THIS PAGE BLANK (USPTO)

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/JP 99/00681

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0184162 A		CN 1056103 A,B	13-11-1991
		DE 3587806 D	01-06-1994
		DE 3587806 T	25-08-1994
		DK 556285 A	04-06-1986
		FI 854731 A,B,	04-06-1986
		FI 864527 A,B	07-11-1986
		GR 852904 A	01-04-1986
		HK 18596 A	09-02-1996
		IE 62865 B	08-03-1995
		JP 2828091 B	25-11-1998
		JP 10067783 A	10-03-1998
		JP 11012281 A	19-01-1999
		JP 1686568 C	11-08-1992
		JP 3046445 B	16-07-1991
		JP 3072483 A	27-03-1991
		JP 1983737 C	25-10-1995
		JP 3072484 A	27-03-1991
		JP 7020970 B	08-03-1995
		JP 2746134 B	28-04-1998
		JP 7224066 A	22-08-1995
		JP 1670486 C	12-06-1992
		JP 3038276 B	10-06-1991
		JP 61148181 A	05-07-1986
		KR 9310704 B	08-11-1993
		KR 9310705 B	08-11-1993
		KR 9310706 B	08-11-1993
		KR 9310707 B	08-11-1993
		KR 9310708 B	08-11-1993
		LU 90317 A	11-01-1999
		MX 9202943 A	30-06-1992
		PT 81589 A,B	01-01-1986
		US 4956352 A	11-09-1990
		US 5624842 A	29-04-1997
		US 5496727 A :	05-03-1996
		US 5110811 A	05-05-1992
		US 5565559 A	15-10-1996
		US 5830717 A	03-11-1998
		US 4894366 A	16-01-1990
		US 4929611 A	29-05-1990
		US 5266692 A	30-11-1993
		US 5254562 A	19-10-1993
		NO 176523 B	09-01-1995

THIS PAGE BLANK (USPTO)